When the Supreme Court rules to preserve mailed mifepristone access (May 14, 2026) while a state lawsuit continues, and two justices dissent by invoking the 19th-century Comstock Act, what do religious traditions and constitutional principles say about federal drug regulation, state authority, and access to medication?
On the substantive question of abortion, religious traditions disagree — and that disagreement is part of why the policy question is so hard. On the procedural question of who decides about medication, religious traditions emphasize subsidiarity but also recognize that some questions genuinely belong at the federal level. The Supreme Court's May 14, 2026 ruling preserves mifepristone access while litigation continues — but the dissents from Justices Alito and Thomas signal where at least part of the Court would go if the right case arrived. Reviving the Comstock Act of 1873 would be one of the most consequential resurrections of dormant law in American history, with implications well beyond abortion. Whatever one thinks about the underlying medication, the question of whether states can override federal drug approvals through litigation is a sweeping regulatory change that deserves to be debated on its own terms, not just as a proxy for the abortion fight.
Religious perspectives
Religious traditions divide on the substantive question of abortion itself — and that disagreement is real and deserves respect. The narrower question here is who gets to decide about medication, and at what level of government.
The substantive divide (recap): Catholic teaching opposes abortion at all stages. Most evangelical Protestant theology aligns with this. Jewish law permits and sometimes requires abortion when the mother's life or health is at stake. Islamic scholars generally permit abortion before ensoulment (~120 days) for serious cause. Mainline Protestant and progressive Jewish/Muslim views often extend further. Religious freedom requires honoring this diversity, not pretending one view is "the religious view."
On access to medication specifically: Many religious traditions place healing in a special moral category — even traditions that have substantive views on the underlying procedure recognize that access to medication and medical care is itself a moral good.
- Judaism: Pikuach nefesh (preserving life) overrides nearly all other commandments. Medications that protect maternal health implicate this principle directly. Even Jewish traditions that oppose elective abortion permit it — and require it — when maternal health is endangered.
- Christianity: The Christian tradition of healing — from Jesus's ministry to the medieval hospitals founded by religious orders to the modern Catholic healthcare system — treats access to medication as a moral good independent of the underlying medical situation.
- Islam: The Prophet Muhammad said "There is no disease that Allah has created, except that He also has created its treatment." Access to lawful medical treatment is itself a moral concern in Islamic ethics, separate from any disagreement about specific interventions.
On subsidiarity — who decides: Catholic social teaching has a specific principle here: subsidiarity. Decisions should be made at the lowest competent level — by individuals where possible, then families, then local communities, then states, then nations. The principle cuts both ways in this debate. Defenders of state-level restrictions invoke it. Defenders of federal medical standards note that subsidiarity recognizes that some questions (drug safety, interstate commerce) genuinely require the higher level. Religious traditions are not all in one place on which level is right; they agree that the question matters.
Constitutional & legal framework
The mifepristone case sits at the intersection of FDA regulatory authority, state police powers, federal preemption, and standing doctrine.
The drug: Mifepristone was approved by the FDA in 2000. It has been used by millions of women since then. FDA scientists have repeatedly affirmed its safety. The drug is approved for use through ten weeks of pregnancy, increasingly via telehealth and mail delivery after FDA regulatory changes in 2021.
The case (2026): Louisiana filed suit challenging the FDA's decision to allow telehealth prescription and mail delivery of mifepristone, arguing the policy undermines Louisiana's state ban and questioning the FDA's safety determinations. On May 1, 2026, the 5th Circuit Court of Appeals blocked telehealth access while litigation continued. Drug manufacturers appealed to the Supreme Court.
The Supreme Court rulings:
- May 4, 2026: Supreme Court temporarily blocked the 5th Circuit ruling while considering the case.
- May 14, 2026: Supreme Court ruled that mailed mifepristone access can continue while the lawsuit plays out, preserving access likely through at least 2026 and into 2027.
The dissents:
- Justice Alito: Dissented, arguing the expanded mail access undermines the Court's prior holding (Dobbs, 2022) that abortion policy should be left to states. Argued that drug manufacturers had not shown irreparable harm.
- Justice Thomas: Separate dissent invoking the Comstock Act of 1873 — a long-dormant law prohibiting mailing of "obscene" materials, which states have begun arguing covers abortion medications. Thomas's dissent signals that at least one justice would revive Comstock as a basis for prohibiting mailed mifepristone nationally.
The Comstock Act question: The 1873 Comstock Act has not been actively enforced for over half a century and was last cited approvingly by the Supreme Court in 1971. Reviving it would represent one of the most significant resurrections of a dormant statute in American legal history. Critics argue Comstock's vague language ("obscene, lewd, lascivious, indecent, filthy, or vile") was crafted in an era of dramatically different constitutional understandings (predating most modern free-speech, privacy, and equal-protection doctrine). Proponents argue the text remains on the books and means what it says.
FDA regulatory authority: Congress in 1962 granted the FDA broad authority to determine drug safety and conditions of use through the Federal Food, Drug, and Cosmetic Act. State efforts to override FDA approval determinations raise federal preemption questions under the Supremacy Clause. Wyeth v. Levine (2009) and Mutual Pharmaceutical v. Bartlett (2013) frame the preemption analysis.
Standing questions: The mifepristone litigation has raised significant standing concerns at every stage. FDA v. Alliance for Hippocratic Medicine (June 2024) found the original anti-mifepristone plaintiffs lacked standing. Louisiana's reframed challenge attempts to use state-as-plaintiff standing, raising questions about whether states can challenge federal drug approvals based on indirect effects on state law.
The deeper structural question: If states can override FDA drug approvals through litigation, drug regulation effectively becomes 50-state rather than federal. That may be a desirable outcome to some and a serious problem to others — but it is a sweeping change to one of the most settled areas of American regulatory law, and one with implications far beyond reproductive medication.
See: FDA mifepristone information → | Comstock Act (18 U.S.C. §1461) →
Sources cited:ConstitutionSupreme Court